Proceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts Oversubscribed Round Includes Public Healthcare Funds CAMBRIDGE, Mass., June 30, 2020-- Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing of an oversubscribed Series B financing, which raised $100 million.